Dopaminergic Neuronal Loss, Reduced Neurite Complexity and Autophagic Abnormalities in Transgenic Mice Expressing G2019S Mutant LRRK2
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene cause late-onset, autosomal dominant familial Parkinson's disease (PD) and also contribute to idiopathic PD. LRRK2 mutations represent the most common cause of PD with clinical and neurochemical features that are largely indistinguishable from idiopathic disease. Currently, transgenic mice expressing wild-type or disease-causing mutants of LRRK2 have failed to produce overt neurodegeneration, although abnormalities in nigrostriatal dopaminergic neurotransmission have been observed. Here, we describe the development and characterization of transgenic mice expressing human LRRK2 bearing the familial PD mutations, R1441C and G2019S. Our study demonstrates that expression of G2019S mutant LRRK2 induces the degeneration of nigrostriatal pathway dopaminergic neurons in an age-dependent manner. In addition, we observe autophagic and mitochondrial abnormalities in the brains of aged G2019S LRRK2 mice and markedly reduced neurite complexity of cultured dopaminergic neurons. These new LRRK2 transgenic mice will provide important tools for understanding the mechanism(s) through which familial mutations precipitate neuronal degeneration and PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4 HPLC analysis of dopamine and its metabolites in G2019S LRRK2 transgenic mice. A–D, Levels of (A) dopamine (DA) and its metabolites, (B) DOPAC and (C) HVA, and (D) dopamine turnover ([DOPAC+HVA]/DA) in the striatum, olfactory bulb and cerebral cortex of 14–15 month-old G2019S LRRK2 TG mice (line 340) and their NTG littermates by HPLC analysis (n = 8/genotype). Bars present the mean ± SEM. *P<0.05 or **P<0.005 comparing TG with NTG as indicated.](https://figures.cochat.ai/paper-figures/2d21c616818941c89c421afafe071ad7/dopaminergic-neuronal-loss-reduced-neurite-complexity-and-autophagic-figure-4.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Dysregulated autophagy has also been associated with the expression of dominant mutants of LRRK2 (leucine‐rich repeat kinase 2) (Ramonet et al, 2011), the most common cause of familial PD.”
From Autophagy in major human diseases (2021) · cites this paper as Ramonet et al, 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology
Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R. J., Calne, D. B., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.11.005 · Cited by 3,005 · cited 2×
“LRRK2-linked PD is characterized by the degeneration of substantia nigra dopaminergic neurons and gliosis together with heterogeneous protein inclusion pathology [3,10].”
BackgroundCloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease
Paisán-Ruı́z, C., Jain, S., Evans, E. W., Gilks, W. P., Simón, J., van der Brug, M., de Munain, A. L., Aparicio, S., Gil, A. M., Khan, N., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.10.023 · Cited by 2,405
Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,765
OPA1 Controls Apoptotic Cristae Remodeling Independently from Mitochondrial Fusion
Frezza, C., Cipolat, S., Martins de Brito, O., Micaroni, M., Beznoussenko, G. V., Rudka, T., Bartoli, D., Polishuck, R. S., Danial, N. N., De Strooper, B., et al. (2006) · Cell · doi:10.1016/j.cell.2006.06.025 · Cited by 1,673 · cited 1×
“area was determined for LRRK2 transgenic (TG) and non-transgenic (NTG) mice. Mitochondria were subclassified as either morphologically normal (class I), damaged (class II) or abnormally condensed/aggregated based upon previously established criteria (”
Healy, D. G., Falchi, M., O'Sullivan, S. S., Bonifati, V., Durr, A., Bressman, S., Brice, A., Aasly, J., Zabetian, C. P., Goldwurm, S., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70117-0 · Cited by 1,425 · cited 1×
“-linked families, including the R1441C/G/H, Y1699C, G2019S and I2020T variants”
BackgroundParkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity
West, A. B., Moore, D. J., Biskup, S., Bugayenko, A., Smith, W. W., Ross, C. A., Dawson, V. L., & Dawson, T. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507360102 · Cited by 1,228 · cited 1×
“1-LRRK2-Myc-His vector [18] was previously modified to introduce a 59 Kozak sequence and 39 stop codon (TAA) between flanking NheI sites.”
Self-citationNew stereological methods for counting neurons
West, M. J. (1993) · Neurobiology of Aging · doi:10.1016/0197-4580(93)90112-o · Cited by 940 · cited 1×
“Unbiased stereological methodology was employed as described previously [55,56] to count TH+ and Nissl+ neurons in the left and right pars compacta region of every fourth section throughout the ventral midbrain.”
MethodA common LRRK2 mutation in idiopathic Parkinson's disease
Gilks, W. P., Abou-Sleiman, P. M., Gandhi, S., Jain, S., Singleton, A., Lees, A. J., Shaw, K., Bhatia, K. P., Bonifati, V., Quinn, N. P., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17830-1 · Cited by 774 · cited 1×
“. Of these, G2019S is the most common variant that uniquely contributes to both familial and sporadic PD”
BackgroundKinase activity is required for the toxic effects of mutant LRRK2/dardarin
Greggio, E., Jain, S., Kingsbury, A., Bandopadhyay, R., Lewis, P., Kaganovich, A., van der Brug, M. P., Beilina, A., Blackinton, J., Thomas, K. J., et al. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.04.001 · Cited by 671 · cited 1×
“LRRK2-induced neuronal toxicity in vitro in a GTP-binding- and kinase-dependent manner [13,19-22], suggesting a gain-of-function mechanism for familial mutations.”
BackgroundLRRK2 G2019S as a Cause of Parkinson's Disease in Ashkenazi Jews
Ozelius, L. J., Senthil, G., Saunders-Pullman, R., Ohmann, E., Deligtisch, A., Tagliati, M., Hunt, A. L., Klein, C., Henick, B., Hailpern, S. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmc055509 · Cited by 665
Cited by
Items 301–400 of 406
Animal models of Parkinson’s disease and related disorders
Petzinger, G. M., & Jakowec, M. W. (2013) · CRC Press eBooks · doi:10.1201/b14361-17 · Cited by 4
Protein Translation in Parkinson’s Disease
Kim, J. W., Abalde-Atristain, L., Jia, H., Martin, I., Dawson, T. M., & Dawson, V. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803783-6.00009-2 · Cited by 4
Self-citationSpiny Projection Neuron Dynamics in Toxin and Transgenic Models of Parkinson’s Disease
Du, Y., & Graves, S. M. (2019) · Frontiers in Neural Circuits · doi:10.3389/fncir.2019.00017 · Cited by 5
“%) degeneration (Ramonet et al., 2011) even in 18–21-month-old animals.”
Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors
Galatsis, P., Henderson, J. L., Kormos, B. L., & Hirst, W. D. (2014) · Topics in medicinal chemistry · doi:10.1007/7355_2014_69 · Cited by 4
“, dopaminergic neuronal loss, α-synuclein accumulation, the development of Lewy bodies, and behavioral phenotype) [75–77], and with the exception of pharmacodynamic end-points, measuring reduction of LRRK2 phosphorylation at S935 and S1292 has not been used, to date, for any long-term LRRK2 inhibitor studies [16].”
BackgroundTowards Small Molecules as Therapies for Alzheimer’s Disease and Other Neurodegenerative Disorders
Aziz, O., Bürli, R. W., Fischer, D. F., Frearson, J. A., & Wall, M. D. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-803959-5.50004-0 · Cited by 6
Kovalenko, V., Александровна, Х. Е., Рзаев, Д. А., & Medvedev, S. P. (2017) · Genes and Cells · doi:10.23868/201707012 · Cited by 4
CAV-2-Mediated GFP and LRRK2G2019S Expression in the Macaca fascicularis Brain
DiCaudo, C., Martínez-Valbuena, I., Mundiñano, I.-C., Gennetier, A., Hernández, M., Carmona‐Abellán, M., Marcilla, I., Kremer, E. J., & Luquín, M. R. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00049 · Cited by 4
“Importantly, the morphological anomalies we found are similar to reports using other LRRK2 forms (Li et al., 2009; Ramonet et al., 2011), and were not found in the HDGFP-injected animals.”
ResultZhu, H., Chen, H., Cho, W., Estrada, A. A., & Sweeney, Z. K. (2013) · Methods and principles in medicinal chemistry · doi:10.1002/9783527677252.ch10 · Cited by 4
The homozygous LRRK2.p.N1437D point mutation mouse is a novel model of parkinsonism
Gan, L., Sun, Y., Zhou, X., Qi, Z.-Y., Liu, F., Tang, Y., Yu, W., Xiao, B., Wang, J., & Wu, J. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-00905-4 · Cited by 3
“The damaged motor ability and loss of dopaminergic neurons only occurred in mice overexpressing R1441C, R1441G, or G2019S mutant LRRK2 6,7,27 .”
InfluentialActinomyces viscosus promotes neuroprotection in C. elegans models of Parkinson’s disease
Ngana, G. S., Bernardo, M. A. D., Surette, M. G., & MacNeil, L. T. (2025) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2025.112061 · Cited by 4
“To determine if aspartic cathepsins prevent neurodegeneration in a model of PD, we measured neurodegeneration in LRRK2 G2019S transgenic animals following RNAi-mediated knockdown of the aspartic cathepsins upregulated by A. viscosus .”
InfluentialHyderi, Z., Farhana, M. S., Singh, T. P., & Ravi, A. V. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149674 · Cited by 4
Enhancement of D1 dopaminergic responses in aged LRRK2 G2019S knock-in mice
Mercatelli, D., Brugnoli, A., Maio, A. D., Albanese, F., Shimshek, D. R., Usiello, A., & Morari, M. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106881 · Cited by 4
“However, these models do not have face validity since, with a few exceptions (Chen et al., 2012; Ramonet et al., 2011; Weng et al., 2016; Xiong et al., 2018), G2019S, R1441G/C or I2020T transgenic rodents and knock-in (KI) mice fail to show main neuropathological and behavioral signatures of PD,…”
What Gene Mutations Affect Serotonin in Mice?
Tenpenny, R. C., & Commons, K. G. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00441 · Cited by 4
Pathogenic LRRK2 requires secondary factors to induce cellular toxicity
Lobbestael, E., den Haute, C. V., Macchi, F., Taymans, J., & Baekelandt, V. (2020) · Bioscience Reports · doi:10.1042/bsr20202225 · Cited by 5
Etiology and pathogenesis of Parkinson’s disease: role of mitochondrial pathology
Brini, M., Ottolini, & Calí, T. (2013) · Research and Reports in Biochemistry · doi:10.2147/rrbc.s28413 · Cited by 6
“61,62 Oxidative stress Compared to glycolysis, in which only two molecules of ATP are produced, the oxidative phosphorylation produces 36 molecules of ATP from one single molecule of glucose.”
Parkinson Disease and Vitamin D: An Interplay Between Genes and the Environment?
DeLuca, G. C. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.1078 · Cited by 3
Giachino, C., Tirolo, C., Caniglia, S., Serapide, M. F., L’Episcopo, F., Bertoli, F., Giuliano, C., Mearelli, M., Jakobi, M., Schneiderhan‐Marra, N., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.01.505977 · Cited by 5
Development of LRRK2 Kinase Inhibitors for Parkinson's Disease
Galatsis, P., Henderson, J. L., Kormos, B. L., & Hirst, W. D. (2014) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-800167-7.00004-3 · Cited by 2
Martinez‐Finley, E. J., Chakraborty, S., Caito, S., Fretham, S. J. B., & Aschner, M. (2012) · PubMed · Cited by 4
LRRK2 G2019S enhances immune response pathways and aggravates asthma in mouse models
Yang, K., Zhou, Y., Cui, J., Tang, W., Chen, Y., & Chen, X. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150593 · Cited by 2
Magen, I., & Chesselet, M. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107360556.031 · Cited by 2
LRRK2 Kinase Inhibitors as New Drugs for Parkinson’s Disease?
Schulz, S., Göring, S., Schmidt, B., & Hopf, C. (2013) · Royal Society of Chemistry eBooks · doi:10.1039/9781849737357-00266 · Cited by 2
Ramonet, D., & Dietz, G. P. H. (2019) · SLAS DISCOVERY · doi:10.1177/2472555219864086 · Cited by 2
“The latter was also used to subclone the open reading frame of KD LRRK2 (without the sequence encoding for GFP) into the pCMV6 vector to create pCMV6-KDLRRK2.”
InfluentialSelf-citationAnimal models of Parkinson's review
You, W. (2021) · AIP conference proceedings · doi:10.1063/5.0050911 · Cited by 2
Steiner, H. (2013) · Basal Ganglia · doi:10.1016/j.baga.2013.04.002 · Cited by 2
“In other cases, such transgenics did display modest alterations in dopamine function/release and/or related behaviors, but, with one exception [24], none showed dopamine neuron degeneration [25–31].”
BackgroundSuzzi, S., Ahrendt, R., Hans, S., Semenova, S. A., Bilican, S., Sayed, S., Winkler, S., Spieß, S., Kaslin, J., Panula, P., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/140608 · Cited by 2
“This result is particularly meaningful considering that brain dopamine and/or catabolite levels are normal in mice lacking endogenous [28, 29] or overexpressing human wild-type LRRK2 [11], but are reduced in mice expressing pathogenic LRRK2 variants, although the effect may be regional [10, 11] or transgene-dependent…”
BackgroundInfluentialShonai, D., Kent, J. K., Okafor, A. E., Gao, Y., Parameswaran, P., Bustamante, E., Ramani, B., Diao, Y., Kampmann, M., Soderblom, E. J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.16.699530 · Cited by 4
Ngo, H. K. C., Srivastava, A., Le, H., Ayer, S. J., Crotty, G. F., Schwarzschild, M. A., & Bakshi, R. (2025) · BMC Neuroscience · doi:10.1186/s12868-025-00939-7 · Cited by 1
“These include loss of dopaminergic neurons, disruption of dopamine homeostasis, which is accompanied by dopamine-dependent behavioral deficits, and α-synucleinopathies [44–46].”
Complex liaisons moving forward the Parkinson’s disease? An appraisal
Rubino, G. (2015) · Basal Ganglia · doi:10.1016/j.baga.2015.09.001 · Cited by 1
Pietropaolo, S., Sluyter, F., & Crusio, W. E. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107360556.030 · Cited by 1
AUTOPHAGY IN HUNTINGTON’S AND PARKINSON’S DISEASES: PATHOGENIC MECHANISMS AND THERAPEUTIC POTENTIALS
Lim, J., Friedman, L. G., McKnight, N. C., & Yue, Z. (2012) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814350457_0011 · Cited by 1
The Role of Alpha-Synuclein Pathology
Fu, Y., Tanglay, O., Li, H., & Halliday, G. M. (2024) · Neuromethods · doi:10.1007/978-1-0716-4083-8_2 · Cited by 2
Control of Autophagy in Parkinson’s Disease
González‐Polo, R. A., Gómez‐Sánchez, R., Pizarro‐Estrella, E., Yakhine-Diop, S. M. S., Rodríguez‐Arribas, M., & Fuentes, J. M. (2015) · Current topics in neurotoxicity · doi:10.1007/978-3-319-13939-5_6 · Cited by 1
The Potential of Targeting LRRK2 in Parkinson’s Disease
Ho, F. Y., Rosenbusch, K. E., & Kortholt, A. (2014) · InTech eBooks · doi:10.5772/57362 · Cited by 3
“Not only overexpression of wildtype and mutant LRRK2 increases accumulation of autophagic vacuoles and the induction of autophagy [56-58], also knocking down LRRK2 activity by either RNAi or with specific LRRK2 inhibitors stimulates autophagy [59].”
BackgroundPluripotent Stem Cell-Derived Dopaminergic Neurons As Models of Neurodegeneration
Watmuff, B., Hartley, B. J., Hunt, C. P. J., Pouton, C. W., & Haynes, J. M. (2013) · Future Neurology · doi:10.2217/fnl.13.50 · Cited by 1
Genetics and Molecular Biology of Parkinson Disease
Petrucci, S., Arena, G., & Valente, E. M. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-405195-9.00015-9 · Cited by 2
Leucine-rich repeat kinase 2 (LRRK2) and Parkinson's disease: from genetics to pathobiology
Cogo, S., & Greggio, E. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815950-7.00001-1 · Cited by 2
Cook, D. A., & Tansey, M. G. (2016) · Springer eBooks · doi:10.1007/978-3-319-44022-4_9 · Cited by 1
Lipid Metabolism in Neurodegenerative Diseases
Lim, L., Shui, G., & Wenk, M. R. (2012) · Wiley eBooks · doi:10.1002/9783527655946.ch14 · Cited by 2
Mathur, N. (2012) · Nottingham ePrints (University of Nottingham) · Cited by 1
Facecchia, K. (2012) · Scholarship at UWindsor (University of Windsor) · Cited by 1
Characterization of FBXO7 (PARK15) knockout mice modeling Parkinsonian-Pyramidal Syndrome
Vingill, S. (2017) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-6254 · Cited by 1
Genetic Models of Parkinson’s Disease
Palubinsky, A. M., Lizama, B. N., Miller, D. L., & McLaughlin, B. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800228-5.00014-5 · Cited by 1
Bureau, S. C. (2022) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2022-14889 · Cited by 1
Autophagic Pathways and Parkinson Disease
Vila, M., & Martínez‐Vicente, M. (2014) · Springer eBooks · doi:10.1007/978-1-4614-5836-4_15
Investigating the Multiple Hit hypothesis of Parkinson disease using transgenic LRRK2-R1441G rats
Shaikh, K. T. (2014) · Scholarship@Western (Western University)
Mount, M. P. (2015) · uO Research (University of Ottawa) · doi:10.20381/ruor-2755
“In addition, recent studies have indicated a putative role for LRRK2 in the regulation of autophagy (Alegre-Abarrategui et al., 2009; Ramonet et al., 2011).”
BackgroundA D. melanogaster parkin mutant larval model of Parkinson's Disease
Vincent, A. (2013) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Mitochondria in Parkinson's Disease
Arena, G., & Valente, E. M. (2015) · Wiley eBooks · doi:10.1002/9781119017127.ch16
LRRK-2 as a Key Molecule Bridging Inflammation to Parkinson's Disease
Roca, V., & Puntel, M. (2013) · Advances in Neuroimmune Biology · doi:10.3233/nib-130067
“, neurite shortening due to G2019S LRRK-2 expression in differentiated SHSY5Y cells [78, 79] and in cultured neurons derived from G2019S LRRK-2 transgenic mice [72], as well as markedly reduced neurite complexity of cultured dopaminergic neurons from brains of aged G2019S LRRK-2 transgenic mice [72].”
BackgroundMethodNetwork modeling to identify new mechanisms and therapeutic targets for Parkinson’s disease
MacArthur, L. H., Ressom, H. W., Shah, S., & Federoff, H. J. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/ern.13.59
“While the role of LRRK2 in PD is not known, it is implicated in the control of neurite length [16,17] , vesicle endocytosis [18] , activation [19] kinase activity is a therapeutic target .”
BackgroundAutophagic Pathology and Calcium Deregulation in Neurodegeneration
Gómez‐Suaga, P., & Hilfiker, S. (2015) · Current topics in neurotoxicity · doi:10.1007/978-3-319-13939-5_13
Neurodegenerative diseases studied in human brain and rodent models
Gellhaar, S. (2015) · Figshare
Exenatide as a novel treatment for Parkinson's Disease
Avilés-Olmos, I. (2013) · UCL Discovery (University College London)
Rodent Models of Autosomal Dominant Parkinson Disease
Xiao, J., Vemula, S. R., & Yue, Z. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-405195-9.00018-4
MODELING LRRK2-ASSOCIATED PARKINSON’S DISEASE IN C. ELEGANS
Yao, C. (2012) · OhioLink ETD Center (Ohio Library and Information Network) · Cited by 1
Basu, S. (2017) · STARS (University of Central Florida) · Cited by 1
The Development of an Inducible Akt as a Potential Gene Therapy for Parkinson’s Disease
Park, S. (2017) · Columbia Academic Commons (Columbia University) · doi:10.7916/d8sb4j50
Parkinson’s Disease and Other Synucleinopathies
Cookson, M. R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811304-2.00006-7
IDENTIFICATION OF NOVEL SUBSTRATES OF LRRK2, A PARKINSON’S DISEASE ASSOCIATED KINASE
Lee, C. H. (2014) · OhioLink ETD Center (Ohio Library and Information Network)
Tsang, A. R. (2018) · Scholarship@Western (Western University)
Dhanushkodi, N. R., & Haque, M. E. (2018) · Springer eBooks · doi:10.1007/978-981-13-0944-1_2
Elucidation of the cell signaling pathways mediating innate immunity and host-pathogen interactions
Nabar, N. R. (2019) · Figshare
Neurochemical Aspects of Lewy Body Dementia
Farooqui, A. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816347-4.00004-0
Role of Interferon-Gamma and Leucine-Rich Repeat Kinase 2 in Stress-Related Pathology
Litteljohn, D. (2016) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2016-11660
Insulin resistance and Parkinson’s disease
Farooqui, A. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819603-8.00007-9
Machine learning discriminates parkinsonian movement disorders in zebrafish
Hughes, G. L. (2019) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Linking the leucine-rich repeat kinase 2 gene, animal models, and Parkinson's disease
Xiong, Y., & Yu, J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815950-7.00044-8
Animal models of Parkinson’s disease and related disorders
Petzinger, G. M., & Jakowec, M. W. (2013) · Informa Healthcare eBooks · doi:10.3109/9781841849096.014
Cresto, N., Gardier, C., Gaillard, M., Gubinelli, F., Roost, P., Molina, D., Joséphine, C., Dufour, N., Aurégan, G., Guillermier, M., et al. (2020) · doi:10.21203/rs.3.rs-24218/v2
Marchetti, B., Giachino, C., Tirolo, C., Caniglia, S., Serapide, M. F., L’Episcopo, F., Bertoli, F., Giuliano, C., Mearelli, M., Jakobi, M., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2044882/v1
Models of Neurodegenerative Diseases
Maharjan, N., & Saxena, S. (2022) · Learning materials in biosciences · doi:10.1007/978-3-031-07793-7_10 · Cited by 1
Cell autonomous role of leucine-rich repeat kinase in protection of dopaminergic neuron survivalPreprint
Kang, J., Huang, G., Ma, L., Tong, Y., Shahapal, A., Chen, P., & Shen, J. (2024) · eLife · doi:10.7554/elife.92673.2 · Cited by 1
Cell autonomous role of leucine-rich repeat kinase in protection of dopaminergic neuron survivalPreprint
Kang, J., Huang, G., Ma, L., Tong, Y., Shahapal, A., Chen, P., & Shen, J. (2024) · eLife · doi:10.7554/elife.92673.3
Low-frequency genetic variants in GAK enhance Golgi function and protect against Parkinson’s diseasePreprint
Calatayud, C., Fernández‐Carasa, I., Spataro, N., Mussolino, C., Richaud‐Patín, Y., Faella, A., Fernández‐Santiago, R., Ezquerra, M., Courtin, T., Bandrés‐Ciga, S., et al. (2025) · medRxiv · doi:10.1101/2025.08.13.25333123 · Cited by 1
“To investigate this possibility further, we quantified the shape and maintenance of the DAn neurite tree, since pathogenic LRRK2 mutations have been associated with shortening and reduced neurite complexity in a variety of experimental models 22,25,28–30 .”
Rodent models for exploring the mechanisms contributing to Parkinson's disease pathophysiology
Allison, J., & Duty, S. (2025) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-443-21992-4.00003-8 · Cited by 1
Lee, J. H., Han, J.-H., Joe, E., & Jou, I. (2021) · Figshare · doi:10.6084/m9.figshare.14921111
Bang, Y., Lee, S., Gal, J., & Choi, H. J. (2026) · Drug Targets and Therapeutics · doi:10.58502/dtt.25.0020
Gubinelli, F. (2019) · theses.fr (ABES) · doi:10.70675/b37261d3zcc7bz45bezb526z9e35982e09bb · Cited by 1
Yildirim-Balatan, C. (2021) · theses.fr (ABES) · doi:10.70675/3372ff2ez69a6z4970z881bze4dfe0a15571
Membrane traffic defects in Parkinson's disease
Filippini, F. (2021) · theses.fr (ABES) · doi:10.70675/f29962a2z9809z4d07z96efz37cc590008b8
Wang, X., Liu, Z.-H., & Smith, W. W. (2026) · Brain Science · doi:10.3390/brainsci16050525
“Functional leucine-rich repeat kinase 2 (LRRK2) modulates substantial intracellular events and neuronal outgrowth essential for neuronal health [67,68].”
Strategies for Optimizing Genetic Mouse Models to Enhance the Understanding of Parkinson’s Disease
Shen, Z., Ma, L., & Mellick, G. D. (2026) · Biomedicines · doi:10.3390/biomedicines14051162
“The expression of LRRK2 p.R1441C in the C57BL/6J strain caused the progressive impairment of locomotor activity [102].”
Do animal models represent the diversity of clinical Parkinson’s disease?
Cenere, M. M., Schirinzi, T., Ledonne, A., & Mercuri, N. B. (2026) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2026.103220
Ortiz, Z. I. (2026) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2026-17091
Ballotto, L., Miglionico, P., Zhao, Y., Bubacco, L., Raimondi, F., Greggio, E., & Manzoni, C. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.17.738869
Merchak, A. R., Herrick, M. K., Houser, M. C., Moustafa, D. A., Goldberg, J. B., Boss, J. M., Kohlmeier, J. E., Cook, D. M., Keating, C. E., Chang, J., et al. (2026) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2026.1860967 · Cited by 1
“LRRK2 regulates multiple cellular processes including neurite outgrowth, cytoskeletal maintenance, and autophagy, all of which are disrupted by mutations in LRRK2 (Plowey et al., 2008; Ramonet et al., 2011; Berwick and Harvey, 2012; Schapansky et al., 2014).”
Mann, L., Herrera-Rodriguez, R., van der Walt, F. E., Brimacombe, K. R., Sadouki, S., Misteli, T., Kubben, N., & Padeken, J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.04.742751
Synthetic Protein Mimetic Based Therapies for Neurodegeneration
Stillman, N. H. (2025) · Digital Commons - DU (University of Denver) · doi:10.56902/etdcrp.2025.171
Cheng, Y.-K., Leong, K.-Q., Lin, P.-J., Chen, M.-J., Lin, C.-Y., Hsiao, Y.-W., Wang, J.-M., Ma, S.-L., Lin, Y., Su, J.-P., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10900990/v1
García‐Swinburn, R., Morón‐Márquez, L., Conde‐Naranjo, C., García‐Roldán, E., Espadas, I., Rodríguez‐Gil, A., Ramírez‐Lorca, R., Villadiego, J., & Toledo‐Aral, J. J. (2026) · Journal of Neurochemistry · doi:10.1111/jnc.70547
“…phenotypes, ranging from the complete absence of neurodegeneration in the nigrostriatal pathway (Garcia-Miralles et al. 2015) to subtle alterations in dopaminergic neurons and minor motor deficits (Ramonet et al. 2011; Yue et al. 2015; Chou et al. 2014; Melrose et al. 2010; Volta et al. 2015).”
Abida, Y., Sghaier, I., Gharbi, A., Souissi, A., Elloumi, M., ATROUS, A., Gargouri, A., Kacem, I., & Gouider, R. (2026) · Acta Neurologica Belgica · doi:10.1007/s13760-026-03203-9
Metadata
- Authors
- Ramonet, D., Daher, J. P. L., Lin, B. M., Stafa, K., Kim, J., Banerjee, R., Westerlund, M., Pletnikova, O., Glauser, L., Yang, L., Liu, Y., Swing, D. A., Beal, M. F., Troncoso, J. C., McCaffery, J. M., Jenkins, N. A., Copeland, N. G., Galter, D., Thomas, B., Lee, M. K., Dawson, T. M., Dawson, V. L., & Moore, D. J.
- Affiliations
- École Polytechnique Fédérale de Lausanne (CH)
- Johns Hopkins University (US)
- University of Minnesota (US)
- Cornell University (US)
- Karolinska Institutet (SE)
- National Cancer Institute (US)
- Corresponding author
- Dawson, Valina L.
- Moore, Darren J.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-04-06
- Volume
- 6
- Issue
- 4
- Pages
- e18568
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3071839
- OpenAlex
- W2166593844
- Cited by
- 405
- References
- 61
- Citations by year
- 2026: 11 · 2025: 15 · 2024: 8 · 2023: 14 · 2022: 23 · 2021: 27 · 2020: 31 · 2019: 28 · 2018: 33 · 2017: 32 · 2016: 27 · 2015: 27 · 2014: 39 · 2013: 36 · 2012: 44
- FWCI
- 26.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- Funders
- National Science Foundation
- National Parkinson Foundation
- American Parkinson Disease Association
- Johns Hopkins University
- École Polytechnique Fédérale de Lausanne
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (127478)
- Vetenskapsrådet
- Parkinson Schweiz
- National Institutes of Health
- Parkinsonfonden
- National Institute of Neurological Disorders and Stroke (R01NS060885, NS060885, NS03877, P50NS038377, NS062165, R21NS062165)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- LRRK2, G2019S mutation, familial Parkinson's disease, transgenic mouse model, dopaminergic neuron loss, nigrostriatal pathway, neurite complexity, autophagy, mitochondrial abnormalities, age-related neurodegeneration
- MeSH terms
- Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Animals, Autophagy, Behavior, Animal, Chromatography, High Pressure Liquid, Dopamine, Humans, Mesencephalon, Mice, Transgenic, Motor Activity, Organ Culture Techniques, Neurites, Protein Serine-Threonine Kinases, Amino Acid Substitution, Protein Transport, Mutant Proteins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.